Literature DB >> 7538781

Mechanism of c-SRC activation in human melanocytes: elevated level of protein tyrosine phosphatase activity directed against the carboxy-terminal regulatory tyrosine.

T J O'Connor1, J D Bjorge, H C Cheng, J H Wang, D J Fujita.   

Abstract

Normal human melanocytes, and some human melanoma cell lines, contain c-SRC which is constitutively activated by hypophosphorylation of tyrosine 530. We investigated the possibility that the activation of c-SRC in melanocytes might be attributable to elevated levels of tyrosine 530-directed protein tyrosine phosphatase activity in these cells. We found three times more of this phosphatase activity in cell extracts from melanocytes compared to fibroblasts. The majority of the tyrosine 530-dephosphorylating activity was present in the particulate fraction of cell homogenates, where c-SRC is also located. Treatment of melanocytes with the protein tyrosine phosphatase inhibitor, sodium orthovanadate, caused inactivation of c-SRC. From these results, we conclude that activation of c-SRC in human melanocytes may be attributed to an elevated level of protein tyrosine phosphatase activity directed against tyrosine 530.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7538781

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  2 in total

Review 1.  Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis.

Authors:  Okkyung Rho; Dae Joon Kim; Karou Kiguchi; John Digiovanni
Journal:  Mol Carcinog       Date:  2010-07-20       Impact factor: 4.784

2.  Csk-homologous kinase (Chk) is an efficient inhibitor of Src-family kinases but a poor catalyst of phosphorylation of their C-terminal regulatory tyrosine.

Authors:  Gahana Advani; Ya Chee Lim; Bruno Catimel; Daisy Sio Seng Lio; Nadia L Y Ng; Anderly C Chüeh; Mai Tran; Mohd Ishtiaq Anasir; Heather Verkade; Hong-Jian Zhu; Benjamin E Turk; Thomas E Smithgall; Ching-Seng Ang; Michael Griffin; Heung-Chin Cheng
Journal:  Cell Commun Signal       Date:  2017-08-07       Impact factor: 5.712

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.